(BEAT) HeartBeam, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BEAT) HeartBeam, Inc. Complete Analysis Pack
HeartBeam’s Business Model, Unpacked in One Smart Snapshot
Unlock the full strategic blueprint behind HeartBeam, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, reaches customers, and positions itself in a fast-moving healthcare market. Ideal for investors, analysts, and entrepreneurs, it’s a smart way to get actionable insight before you buy the full version.
Partnerships
Contract manufacturers
HeartBeam relies on contract manufacturers to build its compact 3D ECG hardware, which uses 5 electrodes and specialized electronics. That setup helps HeartBeam scale a regulated medical device without carrying full factory overhead, while keeping production ready for 2025 commercialization work.
Clinical trial sites
HeartBeam, Inc. depends on hospitals, clinics, and research centers to run validation studies that generate the clinical evidence needed for FDA review and physician trust. These sites also supply real-world patient data that helps refine the device and its 2025-2026 development path.
Regulatory consultants
Regulatory consultants help HeartBeam, Inc. manage FDA submissions, quality systems, and post-market rules. In a high-scrutiny medical device field, that support cuts rework and timeline risk, which matters for a company where one missed filing can delay launch by months.
Cloud and cybersecurity vendors
HeartBeam, Inc. depends on cloud and cybersecurity partners to keep its 3D ECG platform online, store patient data, and encrypt transmission for remote cardiac diagnostics and telemedicine. For a regulated medtech workflow, secure uptime and protected data flow are core to getting clinician-readable ECGs from home use to review.
- Secure cloud hosting supports uptime
- Encryption protects ECG data in transit
- Storage helps remote clinician review
- Cybersecurity lowers patient-data risk
Physician and cardiology advisors
HeartBeam’s physician and cardiology advisors help shape device design, workflow, and ECG interpretation so the product fits real clinical decision making. Their input also supports adoption in cardiology and remote care settings, where faster triage and clearer readings can matter most.
- Clinical input improves usability.
- Aligns with physician decision needs.
- Supports remote cardiac care adoption.
HeartBeam’s Partners Power Its 3D ECG Push Toward FDA Approval
HeartBeam’s key partnerships center on contract manufacturers, clinical sites, regulatory advisers, cloud and cybersecurity vendors, and cardiology experts. These links help it build a 5-electrode 3D ECG device, run validation studies, protect patient data, and move through FDA review for 2025-2026 commercialization.
| Partner | Role |
|---|---|
| Contract manufacturers | Build hardware |
| Clinical sites | Run validation |
| Regulatory advisers | Support FDA work |
| Cloud and security vendors | Host and protect data |
What is included in the product
Detailed Word Document
A concise Business Model Canvas capturing HeartBeam, Inc.’s strategy, customers, channels, and value proposition for investors and analysts.
Customizable Excel Spreadsheet
Simplifies HeartBeam, Inc.’s business model into a quick, editable snapshot that saves time and reduces planning friction.
Reference Sources
Provides a clear source trail for HeartBeam, Inc., boosting credibility and helping stakeholders verify key assumptions fast.
Activities
ECG device development
HeartBeam’s ECG device development centers on a compact 3D ECG platform that captures cardiac signals from 3 orthogonal directions outside a clinic, with work focused on sensors, device shape, and reliability testing. The goal is to turn heart recording into a portable tool that is still clinically useful, and the company’s hardware is built to support repeatable readings in a small form factor.
Cloud software development
HeartBeam, Inc.'s cloud software development centers on a cloud-based diagnostic platform that ingests ECG data, then visualizes, transmits, and helps interpret the signals for remote care. This work is core to its model: HeartBeam reported $0 revenue in its latest filed 2025 results, so the platform is still a build-stage asset, not a scaled service.
Clinical validation studies
HeartBeam must validate its system in studies with real patients and physicians to prove the ECG data is accurate and the workflow fits clinical use. That evidence is central to its FDA 510(k) path and to winning trust from hospitals and clinicians.
Regulatory submissions
HeartBeam, Inc. treats regulatory submissions as a core commercialization step because it has to package FDA-facing evidence on device performance, quality systems, and design controls before approval. For a pre-revenue medtech company, this work directly gates market entry and can absorb a meaningful share of operating spend while filings are prepared.
Regulatory execution is the bridge from product build to sales, and it is often the last major hurdle before scale.
- FDA documentation
- Performance data
- Quality evidence
- Design controls
- Commercialization gate
Manufacturing scale-up
HeartBeam, Inc. must scale from prototype builds to repeatable manufacturing before broad commercialization. That means qualifying suppliers, locking down assembly steps, and tightening quality checks so each unit meets the same standard.
- Supplier qualification
- Repeatable assembly flow
- Quality assurance gates
This step is the bridge between product validation and market launch.
HeartBeam’s 3D ECG Push Is Still Pre-Commercial
HeartBeam, Inc. spends its key effort on building and validating a portable 3D ECG system, with cloud software to capture, transmit, and help interpret cardiac data. In its latest filed 2025 results, HeartBeam reported $0 revenue, so these activities are still pre-commercial and tied to FDA readiness.
| Key activity | Latest data point |
|---|---|
| Revenue | $0 in 2025 |
| Core build focus | 3D ECG device and cloud software |
| Commercial gate | FDA 510(k) path |
Full Document Unlocks After Purchase
Business Model Canvas
This HeartBeam, Inc. Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a live snapshot of the final file, with the same structure, formatting, and content. Once your order is complete, you’ll get full access to this same ready-to-use document for editing, sharing, or presenting.
Resources
Compact ECG device
HeartBeam’s credit card-sized ECG device is the core physical asset in its model, capturing cardiac signals in non-hospital settings and feeding them into remote care workflows. It records 3-dimensional ECG data from 3 leads, and the company positions it as the gateway product for at-home rhythm assessment and faster clinician review.
Cloud diagnostic platform
HeartBeam’s cloud diagnostic platform turns recorded cardiac signals into usable clinical data and supports transmission, review, and analysis, so it is the digital backbone of the service. In HeartBeam, Inc.’s 2025 filings, the Company remained in an early commercial stage, which makes this software layer central to moving from raw signals to clinician-ready results.
Clinical data and algorithms
HeartBeam’s clinical data and software models are core assets because they train diagnostic algorithms on patient ECG data, improving interpretation and product performance over time. For a pre-revenue medtech like HeartBeam, Inc., this kind of proprietary dataset can also raise switching costs for clinicians once workflows are built around the model.
Intellectual property
HeartBeam, Inc.'s intellectual property is a core asset because patents and proprietary know-how protect the device and software stack behind its remote ECG system. That protection helps defend technical differentiation, and it can also support longer-term valuation and future licensing options if the platform gains broader clinical use.
- Protects device and software design
- Defends remote ECG differentiation
- Supports valuation and licensing optionality
Medical and regulatory expertise
HeartBeam, Inc. needs cardiology, engineering, and FDA compliance experts to turn its ECG platform into a clinically useful, regulated device. This matters because FDA 510(k) review targets 90 days, so the right team can cut delay, lower rework risk, and translate features into clear clinical value.
- Cardiology: clinical proof
- Engineering: device reliability
- FDA compliance: faster clearance
HeartBeam’s Core Assets: 3D ECG IP, Cloud Software, and FDA Expertise
HeartBeam’s key resources are its patented 3D ECG device, cloud software, and proprietary ECG data, which together power at-home cardiac monitoring and clinician review. Its 2025 filings still show an early-stage, pre-revenue profile, so FDA/commercial expertise is a critical people asset to move from development to clearance and scale.
| Resource | Why it matters |
|---|---|
| Device IP | Protects the ECG system |
| Cloud platform | Turns signals into reports |
| Clinical data | Trains diagnostics |
| FDA team | Supports clearance |
Value Propositions
Remote cardiac diagnosis
HeartBeam’s remote cardiac diagnosis lets clinicians assess heart symptoms outside the clinic, supporting telemedicine and at-home care. That matters because cardiovascular disease causes about 17.9 million deaths a year worldwide, so earlier remote checks can help catch risk sooner.
Credit card-sized portability
HeartBeam’s credit card-sized design makes 3-lead ECG collection easier to deploy without bulky carts or wired systems, so patients and clinicians can capture data in more places. That portability matters when cardiovascular disease still drives about 1 in 3 deaths worldwide, because faster, simpler access can improve convenience and reach.
Physician-grade diagnostic data
HeartBeam’s platform is built to give clinicians actionable heart data, so physicians can make faster, better care decisions. Better diagnostic detail can improve triage, follow-up, and monitoring, especially when symptoms are intermittent and a single office ECG can miss them.
Outpatient cardiovascular monitoring
HeartBeam’s outpatient cardiovascular monitoring targets patients who need ongoing watch beyond the clinic, fitting chronic care workflows and reducing repeat visits. The need is large: cardiovascular disease causes about 1 in 5 U.S. deaths, so home-based monitoring can keep care continuous and data-rich.
- Supports chronic disease management
- Reduces clinic dependence
- Fits remote care workflows
Telehealth-enabled workflow
HeartBeam’s telehealth-enabled workflow combines portable hardware with cloud software, so clinicians can review ECG data remotely and plug it into telemedicine visits. As of 2025, HeartBeam remained pre-revenue, which makes faster diagnostic access and low-friction remote triage central to its value proposition.
- Hardware plus cloud in one remote tool
- Easier telemedicine integration
- Faster access to diagnostic data
HeartBeam: Portable ECG for Faster, Remote Cardiac Triage
HeartBeam’s value proposition is portable, remote ECG capture that helps clinicians assess symptoms outside the clinic, where a single office ECG can miss intermittent events. This matters in a market where cardiovascular disease caused about 17.9 million deaths worldwide in 2025 and roughly 1 in 5 U.S. deaths. As of 2025, HeartBeam remained pre-revenue, so workflow simplicity and faster triage are key.
| Metric | Value |
|---|---|
| Business stage | Pre-revenue, 2025 |
| Global CVD deaths | 17.9M, 2025 |
| U.S. death share | About 1 in 5 |
Customer Relationships
Physician-led support
HeartBeam, Inc. serves clinicians, so physician trust is the core of the relationship. In 2025, with no meaningful commercial revenue yet, support likely centers on clinical onboarding and interpretation guidance, keeping the workflow aligned with how care is actually delivered.
Remote technical assistance
Remote technical assistance helps HeartBeam, Inc. users set up the device, connect it, and access the software without delays, which matters most in home-based cardiac monitoring. It lowers friction in remote use cases and supports more reliable patient data capture when timely setup and troubleshooting can make or break a monitoring session.
Training and education
HeartBeam must train providers to use its ECG system well, from device setup to data review and clinic workflow. The platform captures 3D vector ECG data from a 3-lead, cable-free device, so clear education is key to faster adoption in care sites and fewer setup errors.
Training also helps clinicians trust and act on the data faster, which matters as HeartBeam moves from development into real-world use.
Account management
HeartBeam’s account management is likely to be hands-on because enterprise healthcare buyers need onboarding, renewal support, and help improving device use. As of 2025, HeartBeam remained pre-commercial, so each customer relationship is critical for retention, pilot conversion, and expansion.
- Onboard hospital teams
- Support renewals and pilots
- Drive usage optimization
- Protect retention and expansion
Clinical workflow integration
HeartBeam’s customer relationship depends on clinical workflow integration: its 3D ECG system is built to fit into provider routines and patient follow-up, which lowers switching friction and supports repeat use. The company says its software converts three-cardiac-vector signals into a 12-lead equivalent ECG, and it won FDA 510(k) clearance for that software in 2024, a key step for easier clinic adoption.
- Fits existing care routines
- Supports follow-up workflows
- Lowers adoption barriers
- Improves repeat use potential
HeartBeam’s clinician-led model is built for trust, training, and workflow fit
HeartBeam’s customer relationship is high-touch and clinician-led, because the company was still pre-commercial in 2025 and depends on trust, onboarding, and training to drive adoption. Its FDA 510(k)-cleared software, approved in 2024, converts 3-vector ECG data into a 12-lead equivalent, so support focuses on fitting into real clinic workflows and reducing setup friction.
| Metric | Value |
|---|---|
| Commercial status, 2025 | Pre-commercial |
| FDA clearance | 510(k), 2024 |
| Device format | 3-lead, cable-free |
| Output | 12-lead equivalent ECG |
Channels
Direct sales to providers
HeartBeam can sell straight to cardiology groups, clinics, and health systems, which is a common medtech route because buyers want clinical proof, workflow fit, and reimbursement detail before they adopt. This one-to-one channel helps HeartBeam explain its value in a market where each provider decision can affect many patients, so every account matters.
Telemedicine partners
Telemedicine partners are a natural channel for HeartBeam, Inc. because they already reach patients outside hospitals and can slot the device into virtual care flows. In 2025, HeartBeam was still in clinical and commercial build-out, so these partners can speed access without needing a full in-person sales force.
Clinical pilot programs
Clinical pilot programs let HeartBeam, Inc. test its 3D ECG system in real-world care settings, so the company can prove accuracy, workflow fit, and patient use before broad rollout. They also create reference sites for future sales, while generating clinical evidence that supports early adoption and payer and provider trust.
Healthcare conferences
Healthcare conferences let HeartBeam, Inc. reach cardiologists and buying teams in person, which matters in a U.S. cardiology market with about 1 million coronary events each year. Meetings also help explain the company’s 3D ECG platform, build clinical trust, and support sales cycles that often need peer review and demo time.
- Reach cardiologists and buyers directly.
- Educate on clinical use and value.
- Build credibility through live demos.
Digital presence
HeartBeam’s digital presence should use its website and online content to explain its 3D ECG platform in plain terms, while educating physicians, investors, and partners. These channels can also support lead generation and brand visibility, which matters for a pre-revenue medtech company focused on clinical adoption and market trust.
- Explain the 3D ECG platform clearly.
- Educate physicians, investors, partners.
- Drive leads and brand visibility online.
HeartBeam’s 2025 Go-to-Market: Direct Sales, Telemedicine, and Pilot Proof
HeartBeam, Inc. can reach cardiology groups, clinics, and health systems through direct sales, while telemedicine partners and pilot sites help fit its 3D ECG into real care workflows. In 2025, this channel mix mattered most because the company was still building clinical proof, so conferences and its website support trust, demos, and lead generation.
| Channel | Use |
|---|---|
| Direct sales | Sell to providers |
| Telemedicine | Expand access |
| Pilots/web | Build proof |
Customer Segments
Cardiologists
Cardiologists are a core user group for ECG diagnostics. In the U.S., heart disease caused 702,880 deaths in 2022, so they need accurate rhythm data for evaluation and follow-up, and HeartBeam’s product is built to support those decisions.
Hospitals and health systems
Hospitals and health systems are a strong customer segment for HeartBeam, Inc. because large providers need remote monitoring to extend care beyond the facility, cut avoidable visits, and tighten workflow. U.S. hospitals manage millions of chronic and cardiac patients each year, so even small gains in triage and follow-up can support enterprise adoption and better patient management.
Primary care clinicians
Primary care clinicians are often the first to see cardiac symptoms, so HeartBeam’s portable 12-lead ECG can help them triage chest pain, palpitations, and other warning signs earlier. That gives them a faster way to decide who needs urgent specialty care, and it extends diagnostic access beyond the clinic.
Telehealth providers
Telehealth providers need remote diagnostic tools that fit digital-first care, and HeartBeam’s 3-lead ECG system is built for that use case. In 2025, this segment matters because virtual care groups can use HeartBeam to capture cardiac data outside the clinic and support faster triage, follow-up, and arrhythmia screening.
- Remote ECG fits virtual care workflows
- 3-lead capture supports home use
- Aligns with telemedicine-led delivery
Patients with cardiovascular disease
Patients with cardiovascular disease are HeartBeam, Inc.'s core end users when they need ongoing cardiac monitoring outside a clinic. The system helps them capture faster rhythm assessments at home, which can speed decisions when symptoms are intermittent.
- Home-based, repeat ECG use
- Faster assessment than office visits
- Fits chronic cardiac monitoring needs
HeartBeam’s ECG Reach Could Speed Cardiac Care Beyond the Clinic
HeartBeam, Inc. sells to cardiologists, hospitals, primary care clinicians, telehealth providers, and patients who need ECG capture outside the clinic. Its reach matters in a market where U.S. heart disease caused 702,880 deaths in 2022, and remote monitoring can speed triage, follow-up, and rhythm review.
| Segment | Why it matters |
|---|---|
| Cardiologists | Diagnostic decisions |
| Hospitals | Remote monitoring |
| Patients | Home ECG use |
Cost Structure
R and D spending
HeartBeam’s R and D is the main cost driver, led by engineering, software, and product development for its ECG hardware and cloud platform. In its latest filing, the company still had no product revenue, so continued R and D spend is central to improving the device, algorithms, and software needed for a medtech launch.
Clinical validation costs
HeartBeam’s clinical validation costs stay heavy because studies, investigators, patient recruitment, and site fees all add up fast. These spends are not optional: they generate the clinical evidence needed to prove device performance and move the product through regulatory review and into the market.
Regulatory and quality costs
HeartBeam, Inc. must keep a full quality system, device files, and compliance records in place, so these costs stay fixed even before sales begin. Regulatory consulting and 510(k)-style submission prep also add overhead; in medical devices, these non-negotiable costs often run alongside years of clinical and engineering work.
Manufacturing and supply chain
HeartBeam’s manufacturing and supply chain costs come from component sourcing, assembly, testing, and regulated logistics, and that pressure rises as a compact medical device moves from pilot builds to scale. In healthcare hardware, supplier reliability and quality control matter most, because a single part failure can force rework, delays, and compliance risk.
- Supplier reliability drives scale-up.
- Testing and QC add fixed costs.
- Logistics must meet medical standards.
Sales marketing and G and A
HeartBeam, Inc.'s sales, marketing, and G&A costs rise as it builds the commercial team, funds customer education, and keeps core admin running. Software hosting and cybersecurity add recurring overhead, and these expenses should climb as the Company shifts from product development to commercialization.
- Commercial hiring raises payroll and benefits.
- Customer education adds launch spending.
- Hosting and cybersecurity create fixed OpEx.
- G&A expands with commercialization.
HeartBeam’s Cash Burn Is Driven by R&D, Trials, and Compliance
HeartBeam, Inc. remains a pre-revenue medtech, so cost structure is led by R and D, clinical trials, and regulatory work, not production scale. In its latest filing, the Company still had no product revenue, which keeps engineering, validation, quality systems, and compliance as the main cash uses.
| Cost item | FY2025 driver |
|---|---|
| R and D | Device and software buildout |
| Clinical | Study and site spend |
| G and A | Admin and compliance |
Revenue Streams
Device sales
Device sales are HeartBeam, Inc.’s clearest direct revenue path: each ECG unit can create one-time hardware income and help place the platform in hospitals, clinics, and cardiology offices. As of its latest public filings, HeartBeam, Inc. was still in a pre-commercial stage, so hardware sales are the first step toward recurring clinical use and broader adoption.
Software subscriptions
HeartBeam, Inc.'s cloud platform can turn remote ECG review into recurring software subscriptions, which is a cleaner model than one-time device sales. In its latest 2025 filing, HeartBeam was still pre-scale on revenue, so software income could become the first high-margin stream as patient monitoring volume grows.
Monitoring service fees
Healthcare customers can pay monthly monitoring and ECG interpretation fees, giving HeartBeam, Inc. recurring revenue tied to patient care. This fits telehealth billing, where CMS remote patient monitoring code 99457 covers at least 20 minutes of clinical management per month, with 99458 adding each extra 20 minutes.
Enterprise licensing
HeartBeam can license its platform to hospitals, health systems, and telemedicine providers, bundling software access and support into one enterprise deal. In its latest public filings, HeartBeam has not yet reported enterprise licensing revenue, so this is still a scale-up channel, not a disclosed income line.
- One contract can cover many clinicians.
- Software access plus support fits enterprise buyers.
- Fewer deals can reach more users fast.
Reimbursement-linked revenue
HeartBeam, Inc. can earn reimbursement-linked revenue when payers cover remote cardiac monitoring, turning each patient workflow into a billable clinical service. That helps provider economics because reimbursable use can lower adoption friction and support broader deployment across outpatient care.
- Payor coverage supports billable monitoring
- Reimbursement can lift provider uptake
- Workflow use can expand recurring revenue
HeartBeam’s Revenue Model: Pre-Commercial Today, Subscription Upside Tomorrow
HeartBeam, Inc. is still pre-revenue in its latest 2025 filing, so its main revenue paths are device sales, recurring software subscriptions, and remote monitoring fees once commercialization starts. Reimbursement-linked billing could support uptake, but no product revenue was reported yet.
| Stream | 2025 status |
|---|---|
| Device sales | Pre-commercial |
| Software and monitoring | Not yet reported |
| Revenue | $0 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.